SOTIO is a biotechnology company developing a new Active Cellular Immunotherapy (“ACI”) based on activated dendritic cells for the treatment of cancer and autoimmune diseases.

SOTIO continues to develop new therapies to address unmet medical needs using its immunotherapy platform and proprietary cell-based technologies.

SOTIO has an active presence in Europe, the United States, China and Russia. Due to its central location, SOTIO’s GMP (Good Manufacturing Practice) certified cell therapy manufacturing facility in Prague can manufacture and supply immunotherapy treatment to meet the needs of its clinical development programs in both Europe and the United States.

In Beijing, China, SOTIO manufactures immunotherapy treatment in its dedicated production facility, built in 2014. SOTIO’s Beijing facility manufactures and supplies immunotherapy treatment for cooperative research projects conducted by leading Chinese hospitals.

SOTIO is a part of PPF Group, one of the largest investment groups in Central and Eastern Europe.